Status: Recruiting
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Participants needed: 50
Trial details
Phase: Phase 1Age: 6-80Biological sex: AllType: InterventionalSponsor: Catherine BollardUpdated: May 31, 2025Locations: 2
Eligibility criteria
Aged 6 months to 80 years. [+6]
Patients with uncontrolled infections. [+35]